SenesTech gets Nasdaq bid price notice, cites record Q3 revenue

SenesTech, Inc. (NASDAQ: SNES) received a notification from The Nasdaq Stock Market LLC on October 20, 2026, stating that its common stock closed below $1.00 per share for 30 consecutive business days. The company currently fails to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Despite the notice, the stock will continue to trade on the Nasdaq Capital Market. SenesTech has until April 19, 2027, to regain compliance with listing rules.

Michael Edell, President and Chief Executive Officer of SenesTech, stated that the company intends to use the compliance period to demonstrate business progress. He cited preliminary third quarter revenue of approximately $1.1 million, which marks the highest in the company's history. This figure represents a 40% increase from the second quarter and a 55% increase from the third quarter of 2025. Edell expressed the belief that continued execution and broader investor awareness could help the share price better reflect the company's value.

Glenbrook Capital Management, a long-term holder with a reported 38% ownership position, congratulated SenesTech on the revenue growth. The firm offered to work cooperatively with the board and management on measures to improve the company's financial position and support operating priorities. SenesTech plans to maintain a disciplined approach to financial management, balancing liquidity needs against the costs of capital and potential dilution to shareholders. The company is currently evaluating its financing requirements and available alternatives to regain compliance with Nasdaq listing rules.

SenesTech positions itself as a leader in rodent birth control and sustainable population management. Its Evolve and ContraPest fertility control solutions, along with assessment and monitoring services, target reproduction to reduce rodent populations in consumer and professional markets. The company notes that its release contains forward-looking statements subject to risks, including the possibility of delisting if compliance is not regained and uncertainties related to market acceptance and financing availability.